TELA Bio Q4 revenue rises 18% to USD 20.9 million as operating loss narrows 20.6% to USD 6.6 million

Reuters03-25

<a href="https://laohu8.com/S/TELA">TELA Bio</a> Q4 revenue rises 18% to USD 20.9 million as operating loss narrows 20.6% to USD 6.6 million

TELA Bio published a quarterly and annual earnings release, reporting Q4 revenue of USD 20.9 million, up 18%, and FY revenue of USD 80.3 million, up 16%.
Q4 gross profit was USD 13.8 million and gross margin was 65.9%, compared with 63.6% a year earlier, reflecting lower excess and obsolete inventory adjustments as a percentage of revenue.
Q4 operating expenses were USD 20.4 million, up 4.23%, driven by higher compensation costs including commissions and severance, as well as higher study and professional fees.
Q4 net loss was USD 9 million and FY net loss was USD 38.8 million.
Management guided for FY 2026 revenue growth of at least 8% and said it closed a credit facility for up to USD 70 million, including an initial USD 60 million loan and an additional USD 10 million available subject to conditions.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. TELA Bio Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603241605PRIMZONEFULLFEED9677892) on March 24, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2622018793?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-25 04:07","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2622018793","market":"fut","top_or_hot":-1,"title":"TELA Bio Q4 revenue rises 18% to USD 20.9 million as operating loss narrows 20.6% to USD 6.6 million","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/TELA\">TELA Bio</a> Q4 revenue rises 18% to USD 20.9 million as operating loss narrows 20.6% to USD 6.6 million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          TELA Bio published a quarterly and annual earnings release, reporting Q4 revenue of USD 20.9 million, up 18%, and FY revenue of USD 80.3 million, up 16%.\n        </li>\n<li>\n          Q4 gross profit was USD 13.8 million and gross margin was 65.9%, compared with 63.6% a year earlier, reflecting lower excess and obsolete inventory adjustments as a percentage of revenue.\n        </li>\n<li>\n          Q4 operating expenses were USD 20.4 million, up 4.23%, driven by higher compensation costs including commissions and severance, as well as higher study and professional fees.\n        </li>\n<li>\n          Q4 net loss was USD 9 million and FY net loss was USD 38.8 million.\n        </li>\n<li>\n          Management guided for FY 2026 revenue growth of at least 8% and said it closed a credit facility for up to USD 70 million, including an initial USD 60 million loan and an additional USD 10 million available subject to conditions.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. TELA Bio Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603241605PRIMZONEFULLFEED9677892) on March 24, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>TELA Bio Q4 revenue rises 18% to USD 20.9 million as operating loss narrows 20.6% to USD 6.6 million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTELA Bio Q4 revenue rises 18% to USD 20.9 million as operating loss narrows 20.6% to USD 6.6 million\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-03-25 04:07</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/TELA\">TELA Bio</a> Q4 revenue rises 18% to USD 20.9 million as operating loss narrows 20.6% to USD 6.6 million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          TELA Bio published a quarterly and annual earnings release, reporting Q4 revenue of USD 20.9 million, up 18%, and FY revenue of USD 80.3 million, up 16%.\n        </li>\n<li>\n          Q4 gross profit was USD 13.8 million and gross margin was 65.9%, compared with 63.6% a year earlier, reflecting lower excess and obsolete inventory adjustments as a percentage of revenue.\n        </li>\n<li>\n          Q4 operating expenses were USD 20.4 million, up 4.23%, driven by higher compensation costs including commissions and severance, as well as higher study and professional fees.\n        </li>\n<li>\n          Q4 net loss was USD 9 million and FY net loss was USD 38.8 million.\n        </li>\n<li>\n          Management guided for FY 2026 revenue growth of at least 8% and said it closed a credit facility for up to USD 70 million, including an initial USD 60 million loan and an additional USD 10 million available subject to conditions.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. TELA Bio Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603241605PRIMZONEFULLFEED9677892) on March 24, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00BKPKM429.USD","symbol_name":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260324:nNDLbG3g0N:1","article_id":"2622018793","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2622018793","pubTimestamp":1774382867,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"TELA Bio published a quarterly and annual earnings release, reporting Q4 revenue of USD 20.9 million, up 18%, and FY revenue of USD 80.3 million, up 16%.Q4 gross profit was USD 13.8 million and gross margin was 65.9%, compared with 63.6% a year earlier, reflecting lower excess and obsolete inventory adjustments as a percentage of revenue.Q4 operating expenses were USD 20.4 million, up 4.23%, driven by higher compensation costs including commissions and severance, as well as higher study and professional fees.Q4 net loss was USD 9 million and FY net loss was USD 38.8 million.Management guided for FY 2026 revenue growth of at least 8% and said it closed a credit facility for up to USD 70 million, including an initial USD 60 million loan and an additional USD 10 million available subject to conditions.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","IE00BN0W2W23.USD":"GUINNESS SUSTAINABLE GLOBAL EQUITY \"C\" (USD) ACC","IE00BN0W2V16.EUR":"GUINNESS SUSTAINABLE GLOBAL EQUITY \"C\" (EUR) ACC","BK4585":"ETF&股票定投概念","BK4198":"医疗保健用品","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","IE00BN0W2T93.GBP":"GUINNESS SUSTAINABLE GLOBAL EQUITY \"C\" (GBP) ACC","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","SG9999014039.USD":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) INC","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","SG9999014005.SGD":"United Global Durable Equities Fund Acc SGD","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","TELA":"TELA Bio, Inc.","SG9999014013.SGD":"United Global Durable Equities Fund Dis SGD","SG9999014021.USD":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) ACC","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","BK4588":"碎股","BK4112":"金融交易所和数据","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","NDAQ":"纳斯达克OMX交易所"},"translate_title":"TELA Bio第四季度收入增长18%至2090万美元，运营亏损收窄20.6%至660万美元","themeId":"ab6e84fb0542480d9cf75cb6a9fe5601","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NDAQ":0.9,"TELA":0.9},"content_text":"TELA Bio Q4 revenue rises 18% to USD 20.9 million as operating loss narrows 20.6% to USD 6.6 million\n    \n\n\n          TELA Bio published a quarterly and annual earnings release, reporting Q4 revenue of USD 20.9 million, up 18%, and FY revenue of USD 80.3 million, up 16%.\n        \n\n          Q4 gross profit was USD 13.8 million and gross margin was 65.9%, compared with 63.6% a year earlier, reflecting lower excess and obsolete inventory adjustments as a percentage of revenue.\n        \n\n          Q4 operating expenses were USD 20.4 million, up 4.23%, driven by higher compensation costs including commissions and severance, as well as higher study and professional fees.\n        \n\n          Q4 net loss was USD 9 million and FY net loss was USD 38.8 million.\n        \n\n          Management guided for FY 2026 revenue growth of at least 8% and said it closed a credit facility for up to USD 70 million, including an initial USD 60 million loan and an additional USD 10 million available subject to conditions.\n        \n\n\n\n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. TELA Bio Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603241605PRIMZONEFULLFEED9677892) on March 24, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2622018793","isCrawlerRequest":true}